Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Mohamed Hassan Sayegh, M.D.

TitleSenior Lecturer on Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressBrigham and Womens Hospital
Transplantation Research Center
221 Longwood Ave
Boston MA 02115
Phone617/732-5259
Fax617/732-5254

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Riella LV, Sayegh MH. T-cell co-stimulatory blockade in transplantation: two steps forward one step back! Expert Opin Biol Ther. 2013 Nov; 13(11):1557-68.
    View in: PubMed
  2. D'Addio F, Ueno T, Clarkson M, Zhu B, Vergani A, Freeman GJ, Sayegh MH, Ansari MJ, Fiorina P, Habicht A. CD160Ig Fusion Protein Targets a Novel Costimulatory Pathway and Prolongs Allograft Survival. PLoS One. 2013; 8(4):e60391.
    View in: PubMed
  3. Vergani A, Fotino C, D'Addio F, Tezza S, Podetta M, Gatti F, Chin M, Bassi R, Molano RD, Corradi D, Gatti R, Ferrero ME, Secchi A, Grassi F, Ricordi C, Sayegh MH, Maffi P, Pileggi A, Fiorina P. Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes. 2013 May; 62(5):1665-75.
    View in: PubMed
  4. Vergani A, Tezza S, D'Addio F, Fotino C, Liu K, Niewczas M, Bassi R, Molano RD, Kleffel S, Petrelli A, Soleti A, Ammirati E, Frigerio M, Visner G, Grassi F, Ferrero ME, Corradi D, Abdi R, Ricordi C, Sayegh MH, Pileggi A, Fiorina P. Long-Term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2X7. Circulation. 2013 Jan 29; 127(4):463-75.
    View in: PubMed
  5. Cousens LP, Najafian N, Mingozzi F, Elyaman W, Mazer B, Moise L, Messitt TJ, Su Y, Sayegh M, High K, Khoury SJ, Scott DW, De Groot AS. In Vitro and In Vivo Studies of IgG-derived Treg Epitopes (Tregitopes): A Promising New Tool for Tolerance Induction and Treatment of Autoimmunity. J Clin Immunol. 2013 Jan; 33 Suppl 1:43-9.
    View in: PubMed
  6. Ueno T, Yeung MY, McGrath M, Yang S, Zaman N, Snawder B, Padera RF, Magee CN, Gorbatov R, Hashiguchi M, Azuma M, Freeman GJ, Sayegh MH, Najafian N. Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses. Eur J Immunol. 2012 Sep; 42(9):2343-53.
    View in: PubMed
  7. Riella LV, Liu T, Yang J, Chock S, Shimizu T, Mfarrej B, Batal I, Xiao X, Sayegh MH, Chandraker A. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant. 2012 Apr; 12(4):846-55.
    View in: PubMed
  8. Carvello M, Petrelli A, Vergani A, Lee KM, Tezza S, Chin M, Orsenigo E, Staudacher C, Secchi A, Dunussi-Joannopoulos K, Sayegh MH, Markmann JF, Fiorina P. Inotuzumab ozogamicin murine analog-mediated B-cell depletion reduces anti-islet allo- and autoimmune responses. Diabetes. 2012 Jan; 61(1):155-65.
    View in: PubMed
  9. De Serres SA, Mfarrej BG, Magee CN, Benitez F, Ashoor I, Sayegh MH, Harmon WE, Najafian N. Immune profile of pediatric renal transplant recipients following alemtuzumab induction. J Am Soc Nephrol. 2012 Jan; 23(1):174-82.
    View in: PubMed
  10. Petrelli A, Carvello M, Vergani A, Lee KM, Tezza S, Du M, Kleffel S, Chengwen L, Mfarrej BG, Hwu P, Secchi A, Leonard WJ, Young D, Sayegh MH, Markmann JF, Zajac AJ, Fiorina P. IL-21 is an antitolerogenic cytokine of the late-phase alloimmune response. Diabetes. 2011 Dec; 60(12):3223-34.
    View in: PubMed
  11. Zhao X, Boenisch O, Yeung M, Mfarrej B, Yang S, Turka LA, Sayegh MH, Iacomini J, Yuan X. Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance. Am J Transplant. 2012 Jan; 12(1):90-101.
    View in: PubMed
  12. D'Addio F, Riella LV, Mfarrej BG, Chabtini L, Adams LT, Yeung M, Yagita H, Azuma M, Sayegh MH, Guleria I. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol. 2011 Nov 1; 187(9):4530-41.
    View in: PubMed
  13. Ueno T, Yamada A, Ito T, Yeung MY, Gorbatov R, Shimizu T, Abdi R, Sayegh MH, Auchincloss H, Najafian N. Role of nuclear factor of activated T cell (NFAT) transcription factors in skin and vascularized cardiac allograft rejection. Transplantation. 2011 Sep 15; 92(5):e26-7.
    View in: PubMed
  14. Ding Q, Yeung M, Camirand G, Zeng Q, Akiba H, Yagita H, Chalasani G, Sayegh MH, Najafian N, Rothstein DM. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest. 2011 Sep; 121(9):3645-56.
    View in: PubMed
  15. El Haddad N, Moore R, Heathcote D, Mounayar M, Azzi J, Mfarrej B, Batal I, Ting C, Atkinson M, Sayegh MH, Ashton-Rickardt PG, Abdi R. The novel role of SERPINB9 in cytotoxic protection of human mesenchymal stem cells. J Immunol. 2011 Sep 1; 187(5):2252-60.
    View in: PubMed
  16. Paterson AM, Brown KE, Keir ME, Vanguri VK, Riella LV, Chandraker A, Sayegh MH, Blazar BR, Freeman GJ, Sharpe AH. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011 Aug 1; 187(3):1097-105.
    View in: PubMed
  17. Yang J, Riella LV, Chock S, Liu T, Zhao X, Yuan X, Paterson AM, Watanabe T, Vanguri V, Yagita H, Azuma M, Blazar BR, Freeman GJ, Rodig SJ, Sharpe AH, Chandraker A, Sayegh MH. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol. 2011 Aug 1; 187(3):1113-9.
    View in: PubMed
  18. Pilat N, Sayegh MH, Wekerle T. Costimulatory pathways in transplantation. Semin Immunol. 2011 Aug; 23(4):293-303.
    View in: PubMed
  19. Mfarrej B, Keir M, Dada S, Trikudanathan S, Sayegh MH, Sharpe AH, Guleria I. Anti-CD3 mAb treatment cures PDL1-/-.NOD mice of diabetes but precipitates fatal myocarditis. Clin Immunol. 2011 Jul; 140(1):47-53.
    View in: PubMed
  20. Sajid MS, Khatri K, Singh K, Sayegh M. Use of staple-line reinforcement in laparoscopic gastric bypass surgery: a meta-analysis. Surg Endosc. 2011 Sep; 25(9):2884-91.
    View in: PubMed
  21. Riella LV, Watanabe T, Sage PT, Yang J, Yeung M, Azzi J, Vanguri V, Chandraker A, Sharpe AH, Sayegh MH, Najafian N. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant. 2011 Apr; 11(4):832-40.
    View in: PubMed
  22. Jurewicz M, Ueno T, Azzi J, Tanaka K, Murayama T, Yang S, Sayegh MH, Niimi M, Abdi R. Donor antioxidant strategy prolongs cardiac allograft survival by attenuating tissue dendritic cell immunogenicity(†). Am J Transplant. 2011 Feb; 11(2):348-55.
    View in: PubMed
  23. Fiorina P, Jurewicz M, Vergani A, Petrelli A, Carvello M, D'Addio F, Godwin JG, Law K, Wu E, Tian Z, Thoma G, Kovarik J, La Rosa S, Capella C, Rodig S, Zerwes HG, Sayegh MH, Abdi R. Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1. J Immunol. 2011 Jan 1; 186(1):121-31.
    View in: PubMed
  24. Sayegh MH. Chronic renal allograft dysfunction (CAD): new frontiers. Introduction. Kidney Int Suppl. 2010 Dec; (119):S1.
    View in: PubMed
  25. El Haddad N, Heathcote D, Moore R, Yang S, Azzi J, Mfarrej B, Atkinson M, Sayegh MH, Lee JS, Ashton-Rickardt PG, Abdi R. Mesenchymal stem cells express serine protease inhibitor to evade the host immune response. Blood. 2011 Jan 27; 117(4):1176-83.
    View in: PubMed
  26. Jurewicz M, Yang S, Augello A, Godwin JG, Moore RF, Azzi J, Fiorina P, Atkinson M, Sayegh MH, Abdi R. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes. 2010 Dec; 59(12):3139-47.
    View in: PubMed
  27. Vergani A, D'Addio F, Jurewicz M, Petrelli A, Watanabe T, Liu K, Law K, Schuetz C, Carvello M, Orsenigo E, Deng S, Rodig SJ, Ansari JM, Staudacher C, Abdi R, Williams J, Markmann J, Atkinson M, Sayegh MH, Fiorina P. A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes. 2010 Sep; 59(9):2253-64.
    View in: PubMed
  28. D'Addio F, Yuan X, Habicht A, Williams J, Ruzek M, Iacomini J, Turka LA, Sayegh MH, Najafian N, Ansari MJ. A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. Transplantation. 2010 Aug 15; 90(3):260-9.
    View in: PubMed
  29. Tian C, Yuan X, Jindra PT, Bagley J, Sayegh MH, Iacomini J. Induction of transplantation tolerance to fully mismatched cardiac allografts by T cell mediated delivery of alloantigen. Clin Immunol. 2010 Aug; 136(2):174-87.
    View in: PubMed
  30. Izawa A, Schatton T, Frank NY, Ueno T, Yamaura K, Pendse SS, Margaryan A, Grimm M, Gasser M, Waaga-Gasser AM, Sayegh MH, Frank MH. A novel in vivo regulatory role of P-glycoprotein in alloimmunity. Biochem Biophys Res Commun. 2010 Apr 9; 394(3):646-52.
    View in: PubMed
  31. Yuan X, Sayegh MH, Iacomini J. Understanding how Tregs are regulated: therapeutic implications. Transplantation. 2009 Nov 27; 88(10):1159-60.
    View in: PubMed
  32. Illigens BM, Yamada A, Anosova N, Dong VM, Sayegh MH, Benichou G. Dual effects of the alloresponse by Th1 and Th2 cells on acute and chronic rejection of allotransplants. Eur J Immunol. 2009 Nov; 39(11):3000-9.
    View in: PubMed
  33. Ayus JC, Achinger SG, Lee S, Sayegh MH, Go AS. Transplant nephrectomy improves survival following a failed renal allograft. J Am Soc Nephrol. 2010 Feb; 21(2):374-80.
    View in: PubMed
  34. Yang J, Riella LV, Boenisch O, Popoola J, Robles S, Watanabe T, Vanguri V, Yuan X, Guleria I, Turka LA, Sayegh MH, Chandraker A. Paradoxical functions of B7: CD28 costimulation in a MHC class II-mismatched cardiac transplant model. Am J Transplant. 2009 Dec; 9(12):2837-44.
    View in: PubMed
  35. Azzi J, Sayegh MH. Clinical transplantation tolerance: a myth no more, but... Am J Kidney Dis. 2009 Dec; 54(6):1005-11.
    View in: PubMed
  36. Tilney N, Murray J, Thistlethwaite R, Norman D, Delmonico F, Hanto D, Leichtman A, Danovitch G, Sayegh M, Shapiro R, Harmon W, Salvatierra O, Brennan D, McDiarmid S, Stock P, Pomfret L, Bennett W, Conti D, Metzger B, Sarwal M, Cosimi AB. Promotion of altruistic donation. Transplantation. 2009 Sep 27; 88(6):847.
    View in: PubMed
  37. De Serres SA, Sayegh MH, Najafian N. Immunosuppressive drugs and Tregs: a critical evaluation! Clin J Am Soc Nephrol. 2009 Oct; 4(10):1661-9.
    View in: PubMed
  38. Yeung MY, Sayegh MH. Regulatory T cells in transplantation: what we know and what we do not know. Transplant Proc. 2009 Jul-Aug; 41(6 Suppl):S21-6.
    View in: PubMed
  39. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol. 2009 Jul 15; 183(2):993-1004.
    View in: PubMed
  40. Yuan X, Ansari MJ, D'Addio F, Paez-Cortez J, Schmitt I, Donnarumma M, Boenisch O, Zhao X, Popoola J, Clarkson MR, Yagita H, Akiba H, Freeman GJ, Iacomini J, Turka LA, Glimcher LH, Sayegh MH. Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci U S A. 2009 Jun 30; 106(26):10734-9.
    View in: PubMed
  41. Fiorina P, Sayegh MH. B cell-targeted therapies in autoimmunity: rationale and progress. F1000 Biol Rep. 2009; 1:39.
    View in: PubMed
  42. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev. 2009 May; 229(1):271-93.
    View in: PubMed
  43. Sayegh MH. Looking into the crystal ball: kidney transplantation in 2025. Nat Clin Pract Nephrol. 2009 Mar; 5(3):117.
    View in: PubMed
  44. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, D'Addio F, Mfarrej B, Donnarumma M, Habicht A, Clarkson MR, Iacomini J, Glimcher LH, Sayegh MH, Ansari MJ. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med. 2008 Dec 22; 205(13):3133-44.
    View in: PubMed
  45. Ansari MJ, Sayegh MH. Complement dances with T cells. Blood. 2008 Sep 1; 112(5):1551-2.
    View in: PubMed
  46. Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes. 2008 Nov; 57(11):3013-24.
    View in: PubMed
  47. Boenisch O, Sayegh MH, Najafian N. Negative T-cell costimulatory pathways: their role in regulating alloimmune responses. Curr Opin Organ Transplant. 2008 Aug; 13(4):373-8.
    View in: PubMed
  48. Porrett PM, Yuan X, LaRosa DF, Walsh PT, Yang J, Gao W, Li P, Zhang J, Ansari JM, Hancock WW, Sayegh MH, Koulmanda M, Strom TB, Turka LA. Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol. 2008 Aug 1; 181(3):1692-9.
    View in: PubMed
  49. Womer KL, Magee CC, Najafian N, Vella JP, Milford EL, Sayegh MH, Carpenter CB. A pilot study on the immunological effects of oral administration of donor major histocompatibility complex class II peptides in renal transplant recipients. Clin Transplant. 2008 Nov-Dec; 22(6):754-9.
    View in: PubMed
  50. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A. 2008 Jul 8; 105(27):9331-6.
    View in: PubMed
  51. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes. 2008 Jul; 57(7):1759-67.
    View in: PubMed
  52. Elyaman W, Kivisäkk P, Reddy J, Chitnis T, Raddassi K, Imitola J, Bradshaw E, Kuchroo VK, Yagita H, Sayegh MH, Khoury SJ. Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol. 2008 Aug; 173(2):411-22.
    View in: PubMed
  53. Ackoundou-N'Guessan C, Gnionsahe A, Guei M, Sayegh M, Kossi S, Tia M, Sissoko DL. High failure rate of first arterio-venous fistula in patients starting hemodialysis treatment: a report from the Ivory Coast. Saudi J Kidney Dis Transpl. 2008 May; 19(3):384-8.
    View in: PubMed
  54. Fiorina P, Jurewicz M, Vergani A, Augello A, Paez J, Ricchiuti V, Tchipachvili V, Sayegh MH, Abdi R. Phenotypic and functional differences between wild-type and CCR2-/- dendritic cells: implications for islet transplantation. Transplantation. 2008 Apr 15; 85(7):1030-8.
    View in: PubMed
  55. Tian C, Yuan X, Bagley J, Blazar BR, Sayegh MH, Iacomini J. Induction of transplantation tolerance by combining non-myeloablative conditioning with delivery of alloantigen by T cells. Clin Immunol. 2008 May; 127(2):130-7.
    View in: PubMed
  56. Sayegh MH, Weiner HL. Regulating rejection with cell therapy. Nat Biotechnol. 2008 Feb; 26(2):191-2.
    View in: PubMed
  57. Ueno T, Habicht A, Clarkson MR, Albin MJ, Yamaura K, Boenisch O, Popoola J, Wang Y, Yagita H, Akiba H, Ansari MJ, Yang J, Turka LA, Rothstein DM, Padera RF, Najafian N, Sayegh MH. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest. 2008 Feb; 118(2):742-51.
    View in: PubMed
  58. Yang J, Popoola J, Khandwala S, Vadivel N, Vanguri V, Yuan X, Dada S, Guleria I, Tian C, Ansari MJ, Shin T, Yagita H, Azuma M, Sayegh MH, Chandraker A. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation. 2008 Feb 5; 117(5):660-9.
    View in: PubMed
  59. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH. Identification of cells initiating human melanomas. Nature. 2008 Jan 17; 451(7176):345-9.
    View in: PubMed
  60. Popoola J, Sayegh MH. Harnessing negative T-cell costimulatory pathways to promote engraftment. Transpl Int. 2008 Jan; 21(1):18-20.
    View in: PubMed
  61. Yang J, Brook MO, Carvalho-Gaspar M, Zhang J, Ramon HE, Sayegh MH, Wood KJ, Turka LA, Jones ND. Allograft rejection mediated by memory T cells is resistant to regulation. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19954-9.
    View in: PubMed
  62. Tian C, Ansari MJ, Paez-Cortez J, Bagley J, Godwin J, Donnarumma M, Sayegh MH, Iacomini J. Induction of robust diabetes resistance and prevention of recurrent type 1 diabetes following islet transplantation by gene therapy. J Immunol. 2007 Nov 15; 179(10):6762-9.
    View in: PubMed
  63. Habicht A, Dada S, Jurewicz M, Fife BT, Yagita H, Azuma M, Sayegh MH, Guleria I. A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol. 2007 Oct 15; 179(8):5211-9.
    View in: PubMed
  64. Tanaka K, Albin MJ, Yuan X, Yamaura K, Habicht A, Murayama T, Grimm M, Waaga AM, Ueno T, Padera RF, Yagita H, Azuma M, Shin T, Blazar BR, Rothstein DM, Sayegh MH, Najafian N. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol. 2007 Oct 15; 179(8):5204-10.
    View in: PubMed
  65. Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, Sayegh MH, Li XC. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo. Am J Transplant. 2007 Dec; 7(12):2683-92.
    View in: PubMed
  66. Ansari MJ, Fiorina P, Dada S, Guleria I, Ueno T, Yuan X, Trikudanathan S, Smith RN, Freeman G, Sayegh MH. Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clin Immunol. 2008 Feb; 126(2):140-7.
    View in: PubMed
  67. Trikudanathan S, Sayegh MH. The evolution of the immunobiology of co-stimulatory pathways: clinical implications. Clin Exp Rheumatol. 2007 Sep-Oct; 25(5 Suppl 46):S12-21.
    View in: PubMed
  68. Habicht A, Najafian N, Yagita H, Sayegh MH, Clarkson MR. New insights in CD28-independent allograft rejection. Am J Transplant. 2007 Aug; 7(8):1917-26.
    View in: PubMed
  69. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med. 2007 Aug; 13(8):952-61.
    View in: PubMed
  70. Ansari MJ, Sayegh MH. The arduous road to achieving an immunosuppression-free state in kidney transplant recipients. Nat Clin Pract Nephrol. 2007 Sep; 3(9):464-5.
    View in: PubMed
  71. Izawa A, Yamaura K, Albin MJ, Jurewicz M, Tanaka K, Clarkson MR, Ueno T, Habicht A, Freeman GJ, Yagita H, Abdi R, Pearson T, Greiner DL, Sayegh MH, Najafian N. A novel alloantigen-specific CD8+PD1+ regulatory T cell induced by ICOS-B7h blockade in vivo. J Immunol. 2007 Jul 15; 179(2):786-96.
    View in: PubMed
  72. Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone JA, Sayegh MH. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol. 2007 Oct; 125(1):16-25.
    View in: PubMed
  73. Xiao S, Najafian N, Reddy J, Albin M, Zhu C, Jensen E, Imitola J, Korn T, Anderson AC, Zhang Z, Gutierrez C, Moll T, Sobel RA, Umetsu DT, Yagita H, Akiba H, Strom T, Sayegh MH, DeKruyff RH, Khoury SJ, Kuchroo VK. Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med. 2007 Jul 9; 204(7):1691-702.
    View in: PubMed
  74. Sayegh MH, Remuzzi G. Clinical update: immunosuppression minimisation. Lancet. 2007 May 19; 369(9574):1676-8.
    View in: PubMed
  75. Salama AD, Womer KL, Sayegh MH. Clinical transplantation tolerance: many rivers to cross. J Immunol. 2007 May 1; 178(9):5419-23.
    View in: PubMed
  76. Guleria I, Sayegh MH. Maternal acceptance of the fetus: true human tolerance. J Immunol. 2007 Mar 15; 178(6):3345-51.
    View in: PubMed
  77. Lacy-Hulbert A, Ueno T, Ito T, Jurewicz M, Izawa A, Smith RN, Chase CM, Tanaka K, Fiorina P, Russell PS, Auchincloss H, Sayegh MH, Hynes RO, Abdi R. Beta 3 integrins regulate lymphocyte migration and cytokine responses in heart transplant rejection. Am J Transplant. 2007 May; 7(5):1080-90.
    View in: PubMed
  78. Fiorina P, Jurewicz M, Tanaka K, Behazin N, Augello A, Vergani A, von Andrian UH, Von Adrian U, Smith NR, Sayegh MH, Abdi R. Characterization of donor dendritic cells and enhancement of dendritic cell efflux with CC-chemokine ligand 21: a novel strategy to prolong islet allograft survival. Diabetes. 2007 Apr; 56(4):912-20.
    View in: PubMed
  79. Methe H, Groothuis A, Sayegh MH, Edelman ER. Matrix adherence of endothelial cells attenuates immune reactivity: induction of hyporesponsiveness in allo- and xenogeneic models. FASEB J. 2007 May; 21(7):1515-26.
    View in: PubMed
  80. St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, Bluestone J. New reagents on the horizon for immune tolerance. Annu Rev Med. 2007; 58:329-46.
    View in: PubMed
  81. Pendse SS, Behjati S, Schatton T, Izawa A, Sayegh MH, Frank MH. P-glycoprotein functions as a differentiation switch in antigen presenting cell maturation. Am J Transplant. 2006 Dec; 6(12):2884-93.
    View in: PubMed
  82. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med. 2006 Nov 27; 203(12):2737-47.
    View in: PubMed
  83. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol. 2006 Oct; 17(10):2844-53.
    View in: PubMed
  84. Ansari MJ, Sayegh MH. Costimulation couture: a designer approach to regulating autoimmunity. J Clin Invest. 2006 Aug; 116(8):2080-3.
    View in: PubMed
  85. Ansari MJ, Sayegh MH. Switching immunosuppressive drugs in kidney transplant recipients: "show me the evidence". Saudi J Kidney Dis Transpl. 2006 Jun; 17(2):149-52.
    View in: PubMed
  86. Harmon W, Meyers K, Ingelfinger J, McDonald R, McIntosh M, Ho M, Spaneas L, Palmer JA, Hawk M, Geehan C, Tinckam K, Hancock WW, Sayegh MH. Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol. 2006 Jun; 17(6):1735-45.
    View in: PubMed
  87. Beaudette-Zlatanova BC, Whalen B, Zipris D, Yagita H, Rozing J, Groen H, Benjamin CD, Hunig T, Drexhage HA, Ansari MJ, Leif J, Mordes JP, Greiner DL, Sayegh MH, Rossini AA. Costimulation and autoimmune diabetes in BB rats. Am J Transplant. 2006 May; 6(5 Pt 1):894-902.
    View in: PubMed
  88. Neujahr DC, Chen C, Huang X, Markmann JF, Cobbold S, Waldmann H, Sayegh MH, Hancock WW, Turka LA. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol. 2006 Apr 15; 176(8):4632-9.
    View in: PubMed
  89. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006 Apr 17; 203(4):883-95.
    View in: PubMed
  90. Zhu B, Guleria I, Khosroshahi A, Chitnis T, Imitola J, Azuma M, Yagita H, Sayegh MH, Khoury SJ. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol. 2006 Mar 15; 176(6):3480-9.
    View in: PubMed
  91. Sayegh MH, Chandraker A. Does belatacept provide equivalent suppression of acute renal transplant rejection to ciclosporin? Nat Clin Pract Nephrol. 2006 Mar; 2(3):134-5.
    View in: PubMed
  92. Fiorina P, Ansari MJ, Jurewicz M, Barry M, Ricchiuti V, Smith RN, Shea S, Means TK, Auchincloss H, Luster AD, Sayegh MH, Abdi R. Role of CXC chemokine receptor 3 pathway in renal ischemic injury. J Am Soc Nephrol. 2006 Mar; 17(3):716-23.
    View in: PubMed
  93. Vu MD, Clarkson MR, Yagita H, Turka LA, Sayegh MH, Li XC. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol. 2006 Feb 1; 176(3):1394-401.
    View in: PubMed
  94. Sánchez-Fueyo A, Sandner S, Habicht A, Mariat C, Kenny J, Degauque N, Zheng XX, Strom TB, Turka LA, Sayegh MH. Specificity of CD4+CD25+ regulatory T cell function in alloimmunity. J Immunol. 2006 Jan 1; 176(1):329-34.
    View in: PubMed
  95. Habicht A, Clarkson MR, Yang J, Henderson J, Brinkmann V, Fernandes S, Jurewicz M, Yuan X, Sayegh MH. Novel insights into the mechanism of action of FTY720 in a transgenic model of allograft rejection: implications for therapy of chronic rejection. J Immunol. 2006 Jan 1; 176(1):36-42.
    View in: PubMed
  96. Iacomini J, Sayegh MH. Measuring T cell alloreactivity to predict kidney transplant outcomes: are we there yet? J Am Soc Nephrol. 2006 Feb; 17(2):328-30.
    View in: PubMed
  97. Hoerbelt R, Johnston DR, Shoji T, Houser SL, Hasse RS, Ledgerwood LG, Iribarne A, Allan JS, Sayegh MH, Sachs DH, Madsen JC. Combination treatment with donor-specific transfusions and cyclosporine a induces long-term survival of cardiac allografts in miniature Swine. Transplantation. 2005 Nov 15; 80(9):1275-82.
    View in: PubMed
  98. Ruiz-Perez B, Chung DR, Sharpe AH, Yagita H, Kalka-Moll WM, Sayegh MH, Kasper DL, Tzianabos AO. Modulation of surgical fibrosis by microbial zwitterionic polysaccharides. Proc Natl Acad Sci U S A. 2005 Nov 15; 102(46):16753-8.
    View in: PubMed
  99. Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation. 2005 Sep 15; 80(5):555-63.
    View in: PubMed
  100. Sho M, Kishimoto K, Harada H, Livak M, Sanchez-Fueyo A, Yamada A, Zheng XX, Strom TB, Basadonna GP, Sayegh MH, Rothstein DM. Requirements for induction and maintenance of peripheral tolerance in stringent allograft models. Proc Natl Acad Sci U S A. 2005 Sep 13; 102(37):13230-5.
    View in: PubMed
  101. Methe H, Nugent HM, Groothuis A, Seifert P, Sayegh MH, Edelman ER. Matrix embedding alters the immune response against endothelial cells in vitro and in vivo. Circulation. 2005 Aug 30; 112(9 Suppl):I89-95.
    View in: PubMed
  102. Guleria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, Yagita H, Noelle RJ, Coyle A, Mellor AL, Khoury SJ, Sayegh MH. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005 Jul 18; 202(2):231-7.
    View in: PubMed
  103. Shoji T, Wain JC, Houser SL, Benjamin LC, Johnston DR, Hoerbelt R, Hasse RS, Lee RS, Muniappan A, Guenther DA, Bravard MA, Ledgerwood LG, Sachs DH, Sayegh MH, Madsen JC, Allan JS. Indirect recognition of MHC class I allopeptides accelerates lung allograft rejection in miniature swine. Am J Transplant. 2005 Jul; 5(7):1626-34.
    View in: PubMed
  104. Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, Yagita H, Azuma M, Sharpe AH, Auchincloss H, Sayegh MH, Najafian N. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol. 2005 Jun 1; 174(11):6648-56.
    View in: PubMed
  105. Lee KM, Forman JP, McNerney ME, Stepp S, Kuppireddi S, Guzior D, Latchman YE, Sayegh MH, Yagita H, Park CK, Oh SB, Wülfing C, Schatzle J, Mathew PA, Sharpe AH, Kumar V. Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions. Blood. 2006 Apr 15; 107(8):3181-8.
    View in: PubMed
  106. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005 May 15; 65(10):4320-33.
    View in: PubMed
  107. Kashizuka H, Sho M, Nomi T, Ikeda N, Kuzumoto Y, Akashi S, Tsurui Y, Mizuno T, Kanehiro H, Yagita H, Nakajima Y, Sayegh MH. Role of the ICOS-B7h costimulatory pathway in the pathophysiology of chronic allograft rejection. Transplantation. 2005 May 15; 79(9):1045-50.
    View in: PubMed
  108. Sandner SE, Clarkson MR, Salama AD, Sanchez-Fueyo A, Domenig C, Habicht A, Najafian N, Yagita H, Azuma M, Turka LA, Sayegh MH. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol. 2005 Mar 15; 174(6):3408-15.
    View in: PubMed
  109. Schenk S, Kish DD, He C, El-Sawy T, Chiffoleau E, Chen C, Chen C, Wu Z, Sandner S, Gorbachev AV, Fukamachi K, Heeger PS, Sayegh MH, Turka LA, Fairchild RL. Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+ CD25+ T cells. J Immunol. 2005 Mar 15; 174(6):3741-8.
    View in: PubMed
  110. Yamada A, Salama AD, Sho M, Najafian N, Ito T, Forman JP, Kewalramani R, Sandner S, Harada H, Clarkson MR, Mandelbrot DA, Sharpe AH, Oshima H, Yagita H, Chalasani G, Lakkis FG, Auchincloss H, Sayegh MH. CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. J Immunol. 2005 Feb 1; 174(3):1357-64.
    View in: PubMed
  111. Tinckam KJ, Sayegh MH. Transplantation tolerance in pediatric recipients: lessons and challenges. Pediatr Transplant. 2005 Feb; 9(1):17-27.
    View in: PubMed
  112. Kutok JL, Yang X, Folkerth RD, Imitola J, Raddassi K, Yano Y, Salahuddin S, Lawitts J, Imboden H, Chinami M, Shirakawa T, Turner H, Khoury S, Sayegh MH, Scadden D, Adra C. The cell cycle associated protein, HTm4, is expressed in differentiating cells of the hematopoietic and central nervous system in mice. J Mol Histol. 2005 Feb; 36(1-2):77-87.
    View in: PubMed
  113. Sandner SE, Clarkson MR, Salama AD, Sanchez-Fueyo A, Yagita H, Turka LA, Sayegh MH. Mechanisms of tolerance induced by donor-specific transfusion and ICOS-B7h blockade in a model of CD4+ T-cell-mediated allograft rejection. Am J Transplant. 2005 Jan; 5(1):31-9.
    View in: PubMed
  114. Sayegh MH, Perico N, Remuzzi G. Transplantation tolerance. A complex scenario awaiting clinical applicability. Contrib Nephrol. 2005; 146:95-104.
    View in: PubMed
  115. Sayegh MH, Carpenter CB. Transplantation 50 years later--progress, challenges, and promises. N Engl J Med. 2004 Dec 23; 351(26):2761-6.
    View in: PubMed
  116. Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet. 2004 Nov 13-19; 364(9447):1814-27.
    View in: PubMed
  117. Denton MD, Magee C, Melter M, Dharnidharka VR, Sayegh MH, Briscoe DM. TNP-470, an angiogenesis inhibitor, attenuates the development of allograft vasculopathy. Transplantation. 2004 Oct 27; 78(8):1218-21.
    View in: PubMed
  118. Kishimoto K, Yuan X, Auchincloss H, Sharpe AH, Mandelbrot DA, Sayegh MH. Mechanism of action of donor-specific transfusion in inducing tolerance: role of donor MHC molecules, donor co-stimulatory molecules, and indirect antigen presentation. J Am Soc Nephrol. 2004 Sep; 15(9):2423-8.
    View in: PubMed
  119. Magee CC, Denton MD, Womer KL, Khoury SJ, Sayegh MH. Assessment by flow cytometry of intracellular cytokine production in the peripheral blood cells of renal transplant recipients. Clin Transplant. 2004 Aug; 18(4):395-401.
    View in: PubMed
  120. Vu MD, Amanullah F, Li Y, Demirci G, Sayegh MH, Li XC. Different costimulatory and growth factor requirements for CD4+ and CD8+ T cell-mediated rejection. J Immunol. 2004 Jul 1; 173(1):214-21.
    View in: PubMed
  121. Poggio ED, Clemente M, Riley J, Roddy M, Greenspan NS, Dejelo C, Najafian N, Sayegh MH, Hricik DE, Heeger PS. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol. 2004 Jul; 15(7):1952-60.
    View in: PubMed
  122. Imitola J, Comabella M, Chandraker AK, Dangond F, Sayegh MH, Snyder EY, Khoury SJ. Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. Am J Pathol. 2004 May; 164(5):1615-25.
    View in: PubMed
  123. Frank MH, Sayegh MH. Immunomodulatory functions of mesenchymal stem cells. Lancet. 2004 May 1; 363(9419):1411-2.
    View in: PubMed
  124. Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity. 2004 May; 20(5):529-38.
    View in: PubMed
  125. Holsti MA, Chitnis T, Panzo RJ, Bronson RT, Yagita H, Sayegh MH, Tzianabos AO. Regulation of postsurgical fibrosis by the programmed death-1 inhibitory pathway. J Immunol. 2004 May 1; 172(9):5774-81.
    View in: PubMed
  126. Sayegh MH, Platt JL. Overview: future approaches to renal replacement and regeneration. J Am Soc Nephrol. 2004 May; 15(5):1105.
    View in: PubMed
  127. Ansari MJ, Sayegh MH. Clinical transplantation tolerance: the promise and challenges. Kidney Int. 2004 May; 65(5):1560-3.
    View in: PubMed
  128. Makhlouf L, Grey ST, Dong V, Csizmadia E, Arvelo MB, Auchincloss H, Ferran C, Sayegh MH. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation. 2004 Apr 15; 77(7):990-7.
    View in: PubMed
  129. Womer KL, Sayegh MH. Donor antigen and transplant tolerance strategies: it takes two to tango! J Am Soc Nephrol. 2004 Apr; 15(4):1101-3.
    View in: PubMed
  130. Chitnis T, Salama AD, Grusby MJ, Sayegh MH, Khoury SJ. Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo. J Immunol. 2004 Apr 1; 172(7):4260-5.
    View in: PubMed
  131. Izawa A, Sayegh MH, Chandraker A. The antagonism of calcineurin inhibitors and costimulatory blockers: fact or fiction? Transplant Proc. 2004 Mar; 36(2 Suppl):570S-573S.
    View in: PubMed
  132. Demirci G, Amanullah F, Kewalaramani R, Yagita H, Strom TB, Sayegh MH, Li XC. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol. 2004 Feb 1; 172(3):1691-8.
    View in: PubMed
  133. Abdi R, Means TK, Ito T, Smith RN, Najafian N, Jurewicz M, Tchipachvili V, Charo I, Auchincloss H, Sayegh MH, Luster AD. Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. J Immunol. 2004 Jan 15; 172(2):767-75.
    View in: PubMed
  134. Rothstein DM, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev. 2003 Dec; 196:85-108.
    View in: PubMed
  135. Ariyan C, Salvalaggio P, Fecteau S, Deng S, Rogozinski L, Mandelbrot D, Sharpe A, Sayegh MH, Basadonna GP, Rothstein DM. Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J Immunol. 2003 Dec 1; 171(11):5673-7.
    View in: PubMed
  136. Reinders ME, Sho M, Izawa A, Wang P, Mukhopadhyay D, Koss KE, Geehan CS, Luster AD, Sayegh MH, Briscoe DM. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest. 2003 Dec; 112(11):1655-65.
    View in: PubMed
  137. Wu Z, Bensinger SJ, Zhang J, Chen C, Yuan X, Huang X, Markmann JF, Kassaee A, Rosengard BR, Hancock WW, Sayegh MH, Turka LA. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med. 2004 Jan; 10(1):87-92.
    View in: PubMed
  138. Salama AD, Chaudhry AN, Holthaus KA, Mosley K, Kalluri R, Sayegh MH, Lechler RI, Pusey CD, Lightstone L. Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney Int. 2003 Nov; 64(5):1685-94.
    View in: PubMed
  139. Sandner SE, Salama AD, Houser SL, Palmer E, Turka LA, Sayegh MH. New TCR transgenic model for tracking allospecific CD4 T-cell activation and tolerance in vivo. Am J Transplant. 2003 Oct; 3(10):1242-50.
    View in: PubMed
  140. Zheng XX, Sánchez-Fueyo A, Sho M, Domenig C, Sayegh MH, Strom TB. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity. 2003 Oct; 19(4):503-14.
    View in: PubMed
  141. Najafian N, Chitnis T, Salama AD, Zhu B, Benou C, Yuan X, Clarkson MR, Sayegh MH, Khoury SJ. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest. 2003 Oct; 112(7):1037-48.
    View in: PubMed
  142. Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, Doeing C, Sayegh MH, Frank MH. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem. 2003 Nov 21; 278(47):47156-65.
    View in: PubMed
  143. Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol. 2003 Sep; 14(9):2402-10.
    View in: PubMed
  144. Makhlouf L, Duvivier-Kali VF, Bonner-Weir S, Dieperink H, Weir GC, Sayegh MH. Importance of hyperglycemia on the primary function of allogeneic islet transplants. Transplantation. 2003 Aug 27; 76(4):657-64.
    View in: PubMed
  145. Pendse S, Sayegh MH, Frank MH. P-glycoprotein--a novel therapeutic target for immunomodulation in clinical transplantation and autoimmunity? Curr Drug Targets. 2003 Aug; 4(6):469-76.
    View in: PubMed
  146. Makhlouf L, Yamada A, Ito T, Abdi R, Ansari MJ, Khuong CQ, Winn HJ, Auchincloss H, Sayegh MH. Allorecognition and effector pathways of islet allograft rejection in normal versus nonobese diabetic mice. J Am Soc Nephrol. 2003 Aug; 14(8):2168-75.
    View in: PubMed
  147. Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, Tushima F, Azuma M, Yagita H, Sayegh MH, Khoury SJ. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003 Jul 7; 198(1):71-8.
    View in: PubMed
  148. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, Yamazaki T, Azuma M, Iwai H, Khoury SJ, Auchincloss H, Sayegh MH. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003 Jul 7; 198(1):63-9.
    View in: PubMed
  149. Harada H, Salama AD, Sho M, Izawa A, Sandner SE, Ito T, Akiba H, Yagita H, Sharpe AH, Freeman GJ, Sayegh MH. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest. 2003 Jul; 112(2):234-43.
    View in: PubMed
  150. Salama AD, Najafian N, Clarkson MR, Harmon WE, Sayegh MH. Regulatory CD25+ T cells in human kidney transplant recipients. J Am Soc Nephrol. 2003 Jun; 14(6):1643-51.
    View in: PubMed
  151. Salama AD, Sayegh MH. Alternative T-cell costimulatory pathways in transplant rejection and tolerance induction: hierarchy or redundancy? Am J Transplant. 2003 May; 3(5):509-11.
    View in: PubMed
  152. Sho M, Harada H, Rothstein DM, Sayegh MH. CD45RB-targeting strategies for promoting long-term allograft survival and preventingchronic allograft vasculopathy. Transplantation. 2003 Apr 27; 75(8):1142-6.
    View in: PubMed
  153. Sayegh MH, Wu Z, Hancock WW, Langmuir PB, Mata M, Sandner S, Kishimoto K, Sho M, Palmer E, Mitchell RN, Turka LA. Allograft rejection in a new allospecific CD4+ TCR transgenic mouse. Am J Transplant. 2003 Apr; 3(4):381-9.
    View in: PubMed
  154. Salama AD, Yuan X, Nayer A, Chandraker A, Inobe M, Uede T, Sayegh MH. Interaction between ICOS-B7RP1 and B7-CD28 costimulatory pathways in alloimmune responses in vivo. Am J Transplant. 2003 Apr; 3(4):390-5.
    View in: PubMed
  155. Murphy B, Yu J, Jiao Q, Lin M, Chitnis T, Sayegh MH. A novel mechanism for the immunomodulatory functions of class II MHC-derived peptides. J Am Soc Nephrol. 2003 Apr; 14(4):1053-65.
    View in: PubMed
  156. Yuan X, Salama AD, Dong V, Schmitt I, Najafian N, Chandraker A, Akiba H, Yagita H, Sayegh MH. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol. 2003 Mar 15; 170(6):2949-55.
    View in: PubMed
  157. Zhai Y, Meng L, Busuttil RW, Sayegh MH, Kupiec-Weglinski JW. Activation of alloreactive CD8+ T cells operates via CD4-dependent and CD4-independent mechanisms and is CD154 blockade sensitive. J Immunol. 2003 Mar 15; 170(6):3024-8.
    View in: PubMed
  158. Sayegh MH, Colvin RB. Case record of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 8-2003. A 35-year-old man with early dysfunction of a second renal transplant. N Engl J Med. 2003 Mar 13; 348(11):1033-44.
    View in: PubMed
  159. Chung DR, Kasper DL, Panzo RJ, Chitnis T, Grusby MJ, Sayegh MH, Tzianabos AO, Chtinis T. CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol. 2003 Feb 15; 170(4):1958-63.
    View in: PubMed
  160. Yamada A, Laufer TM, Gerth AJ, Chase CM, Colvin RB, Russell PS, Sayegh MH, Auchincloss H. Further analysis of the T-cell subsets and pathways of murine cardiac allograft rejection. Am J Transplant. 2003 Jan; 3(1):23-7.
    View in: PubMed
  161. Makhlouf L, Kishimoto K, Smith RN, Abdi R, Koulmanda M, Winn HJ, Auchincloss H, Sayegh MH. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade. Diabetes. 2002 Nov; 51(11):3202-10.
    View in: PubMed
  162. Sho M, Sandner SE, Najafian N, Salama AD, Dong V, Yamada A, Kishimoto K, Harada H, Schmitt I, Sayegh MH. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. Ann Surg. 2002 Nov; 236(5):667-75.
    View in: PubMed
  163. Rolls HK, Kishimoto K, Dong VM, Illigens BM, Sho M, Sayegh MH, Benichou G, Fedoseyeva EV. T-cell response to cardiac myosin persists in the absence of an alloimmune response in recipients with chronic cardiac allograft rejection. Transplantation. 2002 Oct 15; 74(7):1053-7.
    View in: PubMed
  164. Sho M, Yamada A, Najafian N, Salama AD, Harada H, Sandner SE, Sanchez-Fueyo A, Zheng XX, Strom TB, Sayegh MH. Physiological mechanisms of regulating alloimmunity: cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol. 2002 Oct 1; 169(7):3744-51.
    View in: PubMed
  165. Illigens BM, Yamada A, Fedoseyeva EV, Anosova N, Boisgerault F, Valujskikh A, Heeger PS, Sayegh MH, Boehm B, Benichou G. The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Hum Immunol. 2002 Oct; 63(10):912-25.
    View in: PubMed
  166. Zhai Y, Shen XD, Gao F, Coito AJ, Wasowska BA, Salama A, Schmitt I, Busuttil RW, Sayegh MH, Kupiec-Weglinski JW. The CD154-CD40 T cell costimulation pathway is required for host sensitization of CD8(+) T cells by skin grafts via direct antigen presentation. J Immunol. 2002 Aug 1; 169(3):1270-6.
    View in: PubMed
  167. Abdi R, Smith RN, Makhlouf L, Najafian N, Luster AD, Auchincloss H, Sayegh MH. The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes. 2002 Aug; 51(8):2489-95.
    View in: PubMed
  168. Fedoseyeva EV, Kishimoto K, Rolls HK, Illigens BM, Dong VM, Valujskikh A, Heeger PS, Sayegh MH, Benichou G. Modulation of tissue-specific immune response to cardiac myosin can prolong survival of allogeneic heart transplants. J Immunol. 2002 Aug 1; 169(3):1168-74.
    View in: PubMed
  169. Kist-van Holthe JE, Gasser M, Womer K, Najafian N, Dong V, Samsonov DV, Geehan CS, Chandraker A, Sayegh MH, Waaga AM. Regulatory functions of alloreactive Th2 clones in human renal transplant recipients. Kidney Int. 2002 Aug; 62(2):627-31.
    View in: PubMed
  170. Yuan X, Dong VM, Coito AJ, Waaga AM, Salama AD, Benjamin CD, Sayegh MH, Chandraker A. A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection. Transplantation. 2002 Jun 15; 73(11):1736-42.
    View in: PubMed
  171. Chung DR, Chitnis T, Panzo RJ, Kasper DL, Sayegh MH, Tzianabos AO. CD4+ T cells regulate surgical and postinfectious adhesion formation. J Exp Med. 2002 Jun 3; 195(11):1471-8.
    View in: PubMed
  172. Kishimoto K, Sandner S, Imitola J, Sho M, Li Y, Langmuir PB, Rothstein DM, Strom TB, Turka LA, Sayegh MH. Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest. 2002 Jun; 109(11):1471-9.
    View in: PubMed
  173. Salama AD, Sayegh MH. Challenges for the translation of T cell costimulatory blockade therapies to the clinic. Expert Opin Biol Ther. 2002 Jun; 2(5):453-7.
    View in: PubMed
  174. Johnston DR, Sayegh MH, Madsen JC. Overcoming cardiac allograft vasculopathy (CAV) by inducing tolerance. Front Biosci. 2002 May 1; 7:e116-8.
    View in: PubMed
  175. Dong VM, Yuan X, Coito AJ, Waaga AM, Sayegh MH, Chandraker A. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation. 2002 Apr 27; 73(8):1310-7.
    View in: PubMed
  176. Briscoe DM, Sayegh MH. A rendezvous before rejection: where do T cells meet transplant antigens? Nat Med. 2002 Mar; 8(3):220-2.
    View in: PubMed
  177. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol. 2002 Feb; 13(2):559-75.
    View in: PubMed
  178. Laskowski IA, Pratschke J, Wilhelm MJ, Dong VM, Beato F, Taal M, Gasser M, Hancock WW, Sayegh MH, Tilney NL. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol. 2002 Feb; 13(2):519-27.
    View in: PubMed
  179. Yamada And A, Sayegh MH. The CD154-CD40 costimulatory pathway in transplantation. Transplantation. 2002 Jan 15; 73(1 Suppl):S36-9.
    View in: PubMed
  180. Donato JL, Ko J, Kutok JL, Cheng T, Shirakawa T, Mao XQ, Beach D, Scadden DT, Sayegh MH, Adra CN. Human HTm4 is a hematopoietic cell cycle regulator. J Clin Invest. 2002 Jan; 109(1):51-8.
    View in: PubMed
  181. Najafian N, Salama AD, Fedoseyeva EV, Benichou G, Sayegh MH. Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J Am Soc Nephrol. 2002 Jan; 13(1):252-9.
    View in: PubMed
  182. Yamada A, Chandraker A, Laufer TM, Gerth AJ, Sayegh MH, Auchincloss H. Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol. 2001 Nov 15; 167(10):5522-6.
    View in: PubMed
  183. Sho M, Salama AD, Yamada A, Najafian N, Sayegh MH. Physiologic regulation of alloimmune responses in vivo: the role of CTLA4 and TH1/TH2 cytokines. Transplant Proc. 2001 Nov-Dec; 33(7-8):3826-8.
    View in: PubMed
  184. Womer KL, Stone JR, Murphy B, Chandraker A, Sayegh MH. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol. 2001 Nov; 12(11):2500-6.
    View in: PubMed
  185. Rolls HK, Kishimoto K, Illigens BM, Dong V, Sayegh MH, Benichou G, Fedoseyeva EV. Detection of cardiac myosin-specific autoimmunity in a model of chronic heart allograft rejection. Transplant Proc. 2001 Nov-Dec; 33(7-8):3821-2.
    View in: PubMed
  186. Yamada A, Salama AD, Najafian N, Auchincloss H, Sayegh MH. TNF:TNF-R T-Cell costimulatory pathways in transplantation. Transplant Proc. 2001 Nov-Dec; 33(7-8):3070-1.
    View in: PubMed
  187. Salamam AD, Sayegh MH. Achieving clinical transplant tolerance: what are the hurdles? Transplant Proc. 2001 Nov-Dec; 33(7-8):3038-40.
    View in: PubMed
  188. Salama AD, Remuzzi G, Harmon WE, Sayegh MH. Challenges to achieving clinical transplantation tolerance. J Clin Invest. 2001 Oct; 108(7):943-8.
    View in: PubMed
  189. Denton MD, Galvanek EG, Singh A, Sayegh MH. Membranous lupus nephritis in a renal allograft: response to mycophenolate mofetil therapy. Am J Transplant. 2001 Sep; 1(3):288-92.
    View in: PubMed
  190. Najafian N, Khoury SJ, Sayegh MH. T cell costimulatory blockade as a novel immune intervention in autoimmune diseases. Clin Dermatol. 2001 Sep-Oct; 19(5):586-91.
    View in: PubMed
  191. Reznik SI, Jaramillo A, SivaSai KS, Womer KL, Sayegh MH, Trulock EP, Patterson GA, Mohanakumar T. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant. 2001 Sep; 1(3):228-35.
    View in: PubMed
  192. Chitnis T, Najafian N, Benou C, Salama AD, Grusby MJ, Sayegh MH, Khoury SJ. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest. 2001 Sep; 108(5):739-47.
    View in: PubMed
  193. Mandelbrot DA, Kishimoto K, Auchincloss H, Sharpe AH, Sayegh MH. Rejection of mouse cardiac allografts by costimulation in trans. J Immunol. 2001 Aug 1; 167(3):1174-8.
    View in: PubMed
  194. Yamada A, Kishimoto K, Dong VM, Sho M, Salama AD, Anosova NG, Benichou G, Mandelbrot DA, Sharpe AH, Turka LA, Auchincloss H, Sayegh MH. CD28-independent costimulation of T cells in alloimmune responses. J Immunol. 2001 Jul 1; 167(1):140-6.
    View in: PubMed
  195. Azuma H, Takahara S, Matsumoto K, Ichimaru N, Wang JD, Moriyama T, Waaga AM, Kitamura M, Otsuki Y, Okuyama A, Katsuoka Y, Chandraker A, Sayegh MH, Nakamura T. Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol. 2001 Jun; 12(6):1280-92.
    View in: PubMed
  196. Womer KL, Lee RS, Madsen JC, Sayegh MH. Tolerance and chronic rejection. Philos Trans R Soc Lond B Biol Sci. 2001 May 29; 356(1409):727-38.
    View in: PubMed
  197. Womer KL, Sayegh MH, Auchincloss H. Involvement of the direct and indirect pathways of allorecognition in tolerance induction. Philos Trans R Soc Lond B Biol Sci. 2001 May 29; 356(1409):639-47.
    View in: PubMed
  198. Waaga AM, Gasser M, Kist-van Holthe JE, Najafian N, Müller A, Vella JP, Womer KL, Chandraker A, Khoury SJ, Sayegh MH. Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest. 2001 Apr; 107(7):909-16.
    View in: PubMed
  199. Mandelbrot DA, Oosterwegel MA, Shimizu K, Yamada A, Freeman GJ, Mitchell RN, Sayegh MH, Sharpe AH. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. J Clin Invest. 2001 Apr; 107(7):881-7.
    View in: PubMed
  200. Lee RS, Yamada K, Houser SL, Womer KL, Maloney ME, Rose HS, Sayegh MH, Madsen JC. Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy. Proc Natl Acad Sci U S A. 2001 Mar 13; 98(6):3276-81.
    View in: PubMed
  201. Chitnis T, Najafian N, Abdallah KA, Dong V, Yagita H, Sayegh MH, Khoury SJ. CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest. 2001 Mar; 107(5):575-83.
    View in: PubMed
  202. Kim KS, Denton MD, Chandraker A, Knoflach A, Milord R, Waaga AM, Turka LA, Russell ME, Peach R, Sayegh MH. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am J Pathol. 2001 Mar; 158(3):977-86.
    View in: PubMed
  203. Wekerle T, Kurtz J, Sayegh M, Ito H, Wells A, Bensinger S, Shaffer J, Turka L, Sykes M. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol. 2001 Feb 15; 166(4):2311-6.
    View in: PubMed
  204. Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol. 2001 Feb 15; 166(4):2451-9.
    View in: PubMed
  205. Kupiec-Weglinski JW, Shen XD, Gao F, Zhai Y, Coito AJ, Sayegh MH. CD40 ligand-CD40 T cell costimulation pathway is required for host sensitization in the immune cascade leading to accelerated allograft rejection. Transplant Proc. 2001 Feb-Mar; 33(1-2):304-5.
    View in: PubMed
  206. Lee RS, Rusche JR, Maloney ME, Sachs DH, Sayegh MH, Madsen JC. CTLA4Ig-induced linked regulation of allogeneic T cell responses. J Immunol. 2001 Feb 1; 166(3):1572-82.
    View in: PubMed
  207. Lee RS, Yamada K, Houser SL, Womer KL, Maloney ME, Rose HS, Sayegh MH, Madsen JC. Indirect allorecognition promotes the development of cardiac allograft vasculopathy. Transplant Proc. 2001 Feb-Mar; 33(1-2):308-10.
    View in: PubMed
  208. Laskowski IA, Pratschke J, Wilhelm MJ, Paz D, Ames JB, Dong VM, Beato F, Sayegh MH, Hancock WW, Tilney NL. Prolongation of survival and preservation of allograft structure and function by a signaling CD28 mAB in a rat model of chronic kidney rejection. Transplant Proc. 2001 Feb-Mar; 33(1-2):567-8.
    View in: PubMed
  209. Lee RS, Rusche JR, Maloney ME, Sachs DH, Sayegh MH, Madsen JC. CTLA4Ig-induced linked regulation of allogeneic T cell responses. Transplant Proc. 2001 Feb-Mar; 33(1-2):88-9.
    View in: PubMed
  210. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol. 2001 Jan 15; 166(2):973-81.
    View in: PubMed
  211. Fecteau S, Basadonna GP, Freitas A, Ariyan C, Sayegh MH, Rothstein DM. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat Immunol. 2001 Jan; 2(1):58-63.
    View in: PubMed
  212. Rothstein DM, Livak MF, Kishimoto K, Ariyan C, Qian HY, Fecteau S, Sho M, Deng S, Zheng XX, Sayegh MH, Basadonna GP. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long term engraftment and tolerance in stringent transplant models. J Immunol. 2001 Jan 1; 166(1):322-9.
    View in: PubMed
  213. Tzianabos AO, Chandraker A, Kalka-Moll W, Stingele F, Dong VM, Finberg RW, Peach R, Sayegh MH. Bacterial pathogens induce abscess formation by CD4(+) T-cell activation via the CD28-B7-2 costimulatory pathway. Infect Immun. 2000 Dec; 68(12):6650-5.
    View in: PubMed
  214. Frem GJ, Sayegh MH. Post-transplantation hypertension. J Med Liban. 2000 Nov-Dec; 48(6):396-400.
    View in: PubMed
  215. Tran HT, Acharya MK, McKay DB, Sayegh MH, Carpenter CB, Auchincloss H JR, Kirkman RL, Milford EL. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol. 2000 Oct; 11(10):1903-9.
    View in: PubMed
  216. Najafian N, Sayegh MH. CTLA4-Ig: a novel immunosuppressive agent. Expert Opin Investig Drugs. 2000 Sep; 9(9):2147-57.
    View in: PubMed
  217. Kishimoto K, Dong VM, Issazadeh S, Fedoseyeva EV, Waaga AM, Yamada A, Sho M, Benichou G, Auchincloss H, Grusby MJ, Khoury SJ, Sayegh MH. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J Clin Invest. 2000 Jul; 106(1):63-72.
    View in: PubMed
  218. Stadlbauer TH, Schaub M, Magee CC, Kupiec-Weglinski JW, Sayegh MH. Intrathymic immunomodulation in sensitized rat recipients of cardiac allografts: requirements for allorecognition pathways. J Heart Lung Transplant. 2000 Jun; 19(6):566-75.
    View in: PubMed
  219. Aiello S, Noris M, Piccinini G, Tomasoni S, Casiraghi F, Bonazzola S, Mister M, Sayegh MH, Remuzzi G. Thymic dendritic cells express inducible nitric oxide synthase and generate nitric oxide in response to self- and alloantigens. J Immunol. 2000 May 1; 164(9):4649-58.
    View in: PubMed
  220. Wekerle T, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, Shaffer J, Sayegh MH, Sykes M. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med. 2000 Apr; 6(4):464-9.
    View in: PubMed
  221. Issazadeh S, Abdallah K, Chitnis T, Chandraker A, Wells AD, Turka LA, Sayegh MH, Khoury SJ. Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. J Clin Invest. 2000 Apr; 105(8):1109-16.
    View in: PubMed
  222. Lee RS, Yamada K, Womer KL, Pillsbury EP, Allison KS, Marolewski AE, Geng D, Thall AD, Arn JS, Sachs DH, Sayegh MH, Madsen JC. Blockade of CD28-B7, but not CD40-CD154, prevents costimulation of allogeneic porcine and xenogeneic human anti-porcine T cell responses. J Immunol. 2000 Mar 15; 164(6):3434-44.
    View in: PubMed
  223. Reynolds J, Tam FW, Chandraker A, Smith J, Karkar AM, Cross J, Peach R, Sayegh MH, Pusey CD. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest. 2000 Mar; 105(5):643-51.
    View in: PubMed
  224. Kishimoto K, Dong VM, Sayegh MH. The role of costimulatory molecules as targets for new immunosuppressives in transplantation. Curr Opin Urol. 2000 Mar; 10(2):57-62.
    View in: PubMed
  225. Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol. 2000 Mar; 20(2):126-47.
    View in: PubMed
  226. Guttormsen HK, Sharpe AH, Chandraker AK, Brigtsen AK, Sayegh MH, Kasper DL. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect Immun. 1999 Dec; 67(12):6375-84.
    View in: PubMed
  227. Wekerle T, Sayegh MH, Ito H, Hill J, Chandraker A, Pearson DA, Swenson KG, Zhao G, Sykes M. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation. 1999 Nov 15; 68(9):1348-55.
    View in: PubMed
  228. Sayegh MH. Why do we reject a graft? Role of indirect allorecognition in graft rejection. Kidney Int. 1999 Nov; 56(5):1967-79.
    View in: PubMed
  229. Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, Nuñez G, Tang A, Sayegh M, Hancock WW, Strom TB, Turka LA. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med. 1999 Nov; 5(11):1303-7.
    View in: PubMed
  230. Neylan JF, Sayegh MH, Coffman TM, Danovitch GM, Krensky AM, Strom TB, Turka LA, Harmon WE. The allocation of cadaver kidneys for transplantation in the United States: consensus and controversy. ASN Transplant Advisory Group. American Society of Nephrology. J Am Soc Nephrol. 1999 Oct; 10(10):2237-43.
    View in: PubMed
  231. Mackinnon FG, Ho Y, Blake MS, Michon F, Chandraker A, Sayegh MH, Wetzler LM. The role of B/T costimulatory signals in the immunopotentiating activity of neisserial porin. J Infect Dis. 1999 Sep; 180(3):755-61.
    View in: PubMed
  232. Magee CC, Azuma H, Knoflach A, Denton MD, Chandraker A, Iyer S, Buelow R, Sayegh M. In vitro and in vivo immunomodulatory effects of RDP1258, a novel synthetic peptide. J Am Soc Nephrol. 1999 Sep; 10(9):1997-2005.
    View in: PubMed
  233. Denton MD, Geehan CS, Alexander SI, Sayegh MH, Briscoe DM. Endothelial cells modify the costimulatory capacity of transmigrating leukocytes and promote CD28-mediated CD4(+) T cell alloactivation. J Exp Med. 1999 Aug 16; 190(4):555-66.
    View in: PubMed
  234. Dong VM, Womer KL, Sayegh MH. Transplantation tolerance: the concept and its applicability. Pediatr Transplant. 1999 Aug; 3(3):181-92.
    View in: PubMed
  235. Onodera K, Chandraker A, Volk HD, Ritter T, Lehmann M, Kato H, Sayegh MH, Kupiec-Weglinski JW. Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2. Transplantation. 1999 Jul 27; 68(2):288-93.
    View in: PubMed
  236. Saborio DV, Chowdhury NC, Jin MX, Chandraker A, Sayegh MH, Oluwole SF. Regulatory T cells maintain peripheral tolerance to islet allografts induced by intrathymic injection of MHC class I allopeptides. Cell Transplant. 1999 Jul-Aug; 8(4):375-81.
    View in: PubMed
  237. Magee CC, Halligan RD, Milford EL, Sayegh MH. Nocardial infection in a renal transplant recipient on tacrolimus and mycophenolate mofetil. Clin Nephrol. 1999 Jul; 52(1):44-6.
    View in: PubMed
  238. Vella JP, Magee C, Vos L, Womer K, Rennke H, Carpenter CB, Hancock W, Sayegh MH. Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides. Transplantation. 1999 Jun 27; 67(12):1523-32.
    View in: PubMed
  239. Schaub M, Issazadeh S, Stadlbauer TH, Peach R, Sayegh MH, Khoury SJ. Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol. 1999 May 3; 96(2):158-66.
    View in: PubMed
  240. Knoflach A, Azuma H, Magee C, Denton M, Murphy B, Iyengar A, Buelow R, Sayegh MH. Immunomodulatory functions of low-molecular weight hyaluronate in an acute rat renal allograft rejection model. J Am Soc Nephrol. 1999 May; 10(5):1059-66.
    View in: PubMed
  241. Sayegh MH. Finally, CTLA4Ig graduates to the clinic. J Clin Invest. 1999 May; 103(9):1223-5.
    View in: PubMed
  242. Zheng XX, Markees TG, Hancock WW, Li Y, Greiner DL, Li XC, Mordes JP, Sayegh MH, Rossini AA, Strom TB. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol. 1999 Apr 15; 162(8):4983-90.
    View in: PubMed
  243. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999 Mar 27; 353(9158):1083-91.
    View in: PubMed
  244. Knoflach A, Magee C, Denton MD, Kim KS, Buelow R, Hancock WW, Sayegh MH. Immunomodulatory functions of hyaluronate in the LEW-to-F344 model of chronic cardiac allograft rejection. Transplantation. 1999 Mar 27; 67(6):909-14.
    View in: PubMed
  245. Murphy B, Magee CC, Alexander SI, Waaga AM, Snoeck HW, Vella JP, Carpenter CB, Sayegh MH. Inhibition of allorecognition by a human class II MHC-derived peptide through the induction of apoptosis. J Clin Invest. 1999 Mar; 103(6):859-67.
    View in: PubMed
  246. Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka LA. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol. 1999 Feb 15; 162(4):1947-51.
    View in: PubMed
  247. Zheng XX, Li Y, Li XC, Roy-Chaudhury P, Nickerson P, Tian Y, Sayegh MH, Strom TB. Blockade of CD40L/CD40 costimulatory pathway in a DST presensitization model of islet allograft leads to a state of Allo-Ag specific tolerance and permits subsequent engraftment of donor strain islet or heart allografts. Transplant Proc. 1999 Feb-Mar; 31(1-2):627-8.
    View in: PubMed
  248. Wekerle T, Sayegh MH, Chandraker A, Swenson KG, Zhao Y, Sykes M. Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade. Transplant Proc. 1999 Feb-Mar; 31(1-2):680.
    View in: PubMed
  249. Azuma H, Takahara S, Kitamura M, Wang JD, Wega A, Sayegh MH, Suzuki S, Matsumoto K, Nakamura T, Okuyama A, Katsuoka Y. Effect of hepatocyte growth factor on chronic rejection in rat renal allografts. Transplant Proc. 1999 Feb-Mar; 31(1-2):854-5.
    View in: PubMed
  250. Onodera K, Chandraker A, Kato H, Volk HD, Sayegh MH, Kupiec-Weglinski JW. Distinct tolerance pathways in sensitized rat recipients after blockade of activation signal 1 and signal 2. Transplant Proc. 1999 Feb-Mar; 31(1-2):876-7.
    View in: PubMed
  251. Issazadeh S, Zhang M, Sayegh MH, Khoury SJ. Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model. J Immunol. 1999 Jan 15; 162(2):761-5.
    View in: PubMed
  252. Khoury S, Sayegh MH, Turka LA. Blocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease. Int Rev Immunol. 1999; 18(3):185-99.
    View in: PubMed
  253. Hancock WW, Buelow R, Sayegh MH, Turka LA. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med. 1998 Dec; 4(12):1392-6.
    View in: PubMed
  254. Vella JP, Sayegh MH, Turka LA. Developments in the clinical science of transplantation during the 20th century. Pediatr Transplant. 1998 Nov; 2(4):257-62.
    View in: PubMed
  255. Mark DA, Donovan CE, De Sanctis GT, Krinzman SJ, Kobzik L, Linsley PS, Sayegh MH, Lederer J, Perkins DL, Finn PW. Both CD80 and CD86 co-stimulatory molecules regulate allergic pulmonary inflammation. Int Immunol. 1998 Nov; 10(11):1647-55.
    View in: PubMed
  256. Chowdhury NC, Saborio DV, Garrovillo M, Chandraker A, Magee CC, Waaga AM, Sayegh MH, Jin MX, Oluwole SF. Comparative studies of specific acquired systemic tolerance induced by intrathymic inoculation of a single synthetic Wistar-Furth (RT1U) allo-MHC class I (RT1.AU) peptide or WAG (RT1U)-derived class I peptide. Transplantation. 1998 Oct 27; 66(8):1059-66.
    View in: PubMed
  257. Issazadeh S, Navikas V, Schaub M, Sayegh M, Khoury S. Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo. J Immunol. 1998 Aug 1; 161(3):1104-12.
    View in: PubMed
  258. Magee CC, Sayegh MH. Peptide mediated immunosuppression: new developments. Transplant Proc. 1998 Aug; 30(5):2131-5.
    View in: PubMed
  259. Takada M, Nadeau KC, Hancock WW, Mackenzie HS, Shaw GD, Waaga AM, Chandraker A, Sayegh MH, Tilney NL. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation. 1998 Jun 27; 65(12):1533-42.
    View in: PubMed
  260. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med. 1998 Jun 18; 338(25):1813-21.
    View in: PubMed
  261. Wekerle T, Sayegh MH, Hill J, Zhao Y, Chandraker A, Swenson KG, Zhao G, Sykes M. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med. 1998 Jun 15; 187(12):2037-44.
    View in: PubMed
  262. Chandraker A, Azuma H, Nadeau K, Carpenter CB, Tilney NL, Hancock WW, Sayegh MH. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest. 1998 Jun 1; 101(11):2309-18.
    View in: PubMed
  263. Kato H, Onodera K, Chandraker A, Volk HD, Sayegh MH, Kupiec-Weglinski JW. CD4-targeted therapy and CD28-B7 costimulatory blockage may independently induce tolerance in sensitized allograft recipients. Transplant Proc. 1998 Jun; 30(4):1063-4.
    View in: PubMed
  264. Schaub M, Stadlbauer TH, Chandraker A, Vella JP, Turka LA, Sayegh MH. Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen. J Am Soc Nephrol. 1998 May; 9(5):891-8.
    View in: PubMed
  265. Waaga AM, Chandraker A, Spadafora-Ferreira M, Iyengar AR, Khoury SJ, Carpenter CB, Sayegh MH. Mechanisms of indirect allorecognition: characterization of MHC class II allopeptide-specific T helper cell clones from animals undergoing acute allograft rejection. Transplantation. 1998 Apr 15; 65(7):876-83.
    View in: PubMed
  266. Parr MJ, Wen PY, Schaub M, Khoury SJ, Sayegh MH, Fine HA. Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol. 1998 Apr; 4(2):194-203.
    View in: PubMed
  267. Chertow GM, Lazarus JM, Paganini EP, Allgren RL, Lafayette RA, Sayegh MH. Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group. J Am Soc Nephrol. 1998 Apr; 9(4):692-8.
    View in: PubMed
  268. Oliveira G, Xavier P, Murphy B, Neto S, Mendes A, Sayegh MH, Guerra LE. Cytokine analysis of human renal allograft aspiration biopsy cultures supernatants predicts acute rejection. Nephrol Dial Transplant. 1998 Feb; 13(2):417-22.
    View in: PubMed
  269. Vella JP, Sayegh MH. Interactions between cyclosporine and newer antidepressant medications. Am J Kidney Dis. 1998 Feb; 31(2):320-3.
    View in: PubMed
  270. Onodera K, Chandraker A, Korom S, Stadlbauer TH, Kato K, Kasai S, Sayegh MH, Kupiec-Weglinski JW. Agonistic and antagonistic interactions between CTLA4Ig and donor alloantigens in sensitized rat recipients of cardiac allografts. Transplant Proc. 1998 Feb; 30(1):16-8.
    View in: PubMed
  271. Chen W, Sayegh MH, Khoury SJ. Mechanisms of acquired thymic tolerance in vivo: intrathymic injection of antigen induces apoptosis of thymocytes and peripheral T cell anergy. J Immunol. 1998 Feb 1; 160(3):1504-8.
    View in: PubMed
  272. Onodera K, Chandraker A, Volk HD, Lehmann M, Korom S, Stadlbauer TH, Kato K, Kasai S, Sayegh MH, Kupiec-Weglinski JW. Role of regulatory T cells in the "infectious" tolerance pathway in transplant recipients. Transplant Proc. 1998 Feb; 30(1):13-5.
    View in: PubMed
  273. Glysing-Jensen T, Räisänen-Sokolowski A, Sayegh MH, Russell ME. Chronic blockade of CD28-B7-mediated T-cell costimulation by CTLA4Ig reduces intimal thickening in MHC class I and II incompatible mouse heart allografts. Transplantation. 1997 Dec 27; 64(12):1641-5.
    View in: PubMed
  274. Sun H, Subbotin V, Chen C, Aitouche A, Valdivia LA, Sayegh MH, Linsley PS, Fung JJ, Starzl TE, Rao AS. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. Transplantation. 1997 Dec 27; 64(12):1838-43.
    View in: PubMed
  275. Stadlbauer TH, Schaub M, Korom S, Onodera K, Sayegh MH, Kupiec-Weglinski JW. CD28-B7 T-cell co-stimulatory blockade potentiates the effects of intrathymic immunomodulation in sensitized graft recipients. Transplantation. 1997 Dec 27; 64(12):1816-22.
    View in: PubMed
  276. Vella JP, Vos L, Carpenter CB, Sayegh MH. Role of indirect allorecognition in experimental late acute rejection. Transplantation. 1997 Dec 27; 64(12):1823-8.
    View in: PubMed
  277. Sayegh MH, Zheng XG, Magee C, Hancock WW, Turka LA. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation. 1997 Dec 27; 64(12):1646-50.
    View in: PubMed
  278. Chandraker A, Takada M, Nadeau KC, Peach R, Tilney NL, Sayegh MH. CD28-b7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury. Kidney Int. 1997 Dec; 52(6):1678-84.
    View in: PubMed
  279. Gallon L, Chandraker A, Issazadeh S, Peach R, Linsley PS, Turka LA, Sayegh MH, Khoury SJ. Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model. J Immunol. 1997 Nov 1; 159(9):4212-6.
    View in: PubMed
  280. Magee CC, Sayegh MH. Peptide-mediated immunosuppression. Curr Opin Immunol. 1997 Oct; 9(5):669-75.
    View in: PubMed
  281. Vella JP, Spadafora-Ferreira M, Murphy B, Alexander SI, Harmon W, Carpenter CB, Sayegh MH. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation. 1997 Sep 27; 64(6):795-800.
    View in: PubMed
  282. Hancock WW, Miyatake T, Koyamada N, Kut JP, Soares M, Russell ME, Bach FH, Sayegh MH. Effects of leflunomide and deoxyspergualin in the guinea pig-->rat cardiac model of delayed xenograft rejection: suppression of B cell and C-C chemokine responses but not induction of macrophage lectin. Transplantation. 1997 Sep 15; 64(5):696-704.
    View in: PubMed
  283. Schaub M, Stadlbauer TH, Sayegh MH. CTLA4Ig: effects on cellular and humoral immunity and macrophage activation. Exp Nephrol. 1997 Sep-Oct; 5(5):370-4.
    View in: PubMed
  284. Vella JP, Sayegh MH. Current and future immunosuppressive therapies: impact on chronic allograft dysfunction. J Nephrol. 1997 Sep-Oct; 10(5):229-31.
    View in: PubMed
  285. Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL. The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest. 1997 Sep 1; 100(5):1199-203.
    View in: PubMed
  286. Onodera K, Chandraker A, Schaub M, Stadlbauer TH, Korom S, Peach R, Linsley PS, Sayegh MH, Kupiec-Weglinski JW. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses. J Immunol. 1997 Aug 15; 159(4):1711-7.
    View in: PubMed
  287. Zheng XX, Sayegh MH, Zheng XG, Li Y, Linsley PS, Peach R, Borriello F, Strom TB, Sharpe AH, Turka LA. The role of donor and recipient B7-1 (CD80) in allograft rejection. J Immunol. 1997 Aug 1; 159(3):1169-73.
    View in: PubMed
  288. Chen W, Issazadeh S, Sayegh MH, Khoury SJ. In vivo mechanisms of acquired thymic tolerance. Cell Immunol. 1997 Aug 1; 179(2):165-73.
    View in: PubMed
  289. Murphy B, Kim KS, Buelow R, Sayegh MH, Hancock WW. Synthetic MHC class I peptide prolongs cardiac survival and attenuates transplant arteriosclerosis in the Lewis-->Fischer 344 model of chronic allograft rejection. Transplantation. 1997 Jul 15; 64(1):14-9.
    View in: PubMed
  290. Vella JP, Sayegh MH. Maintenance pharmacological immunosuppressive strategies in renal transplantation. Postgrad Med J. 1997 Jul; 73(861):386-90.
    View in: PubMed
  291. Vella JP, Mosher R, Sayegh MH. Kaposi's sarcoma after renal transplantation. N Engl J Med. 1997 Jun 12; 336(24):1761.
    View in: PubMed
  292. Korom S, De Meester I, Stadlbauer TH, Chandraker A, Schaub M, Sayegh MH, Belyaev A, Haemers A, Scharpé S, Kupiec-Weglinski JW. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation. 1997 May 27; 63(10):1495-500.
    View in: PubMed
  293. Onodera K, Lehmann M, Volk HD, Sayegh MH, Kupiec-Weglinski JW. CD4-targeted therapy induces "infectious" tolerance to cardiac allografts in sensitized rat recipients. Transplant Proc. 1997 May; 29(3):1907-8.
    View in: PubMed
  294. Chandraker A, Russell ME, Glysing-Jensen T, Willett TA, Sayegh MH. T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen. Transplantation. 1997 Apr 27; 63(8):1053-8.
    View in: PubMed
  295. Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, Sweet RM, Genter FC, Kurnik BR, Conger JD, Sayegh MH. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med. 1997 Mar 20; 336(12):828-34.
    View in: PubMed
  296. Akalin E, Chandraker A, Sayegh M, Turka LA. Role of the CD28:B7 costimulatory interaction in alloimmune responses. Kidney Int Suppl. 1997 Mar; 58:S8-10.
    View in: PubMed
  297. Sayegh MH, Carpenter CB. Tolerance and chronic rejection. Kidney Int Suppl. 1997 Mar; 58:S11-4.
    View in: PubMed
  298. Onodera K, Hancock WW, Graser E, Lehmann M, Sayegh MH, Strom TB, Volk HD, Kupiec-Weglinski JW. Type 2 helper T cell-type cytokines and the development of "infectious" tolerance in rat cardiac allograft recipients. J Immunol. 1997 Feb 15; 158(4):1572-81.
    View in: PubMed
  299. Waaga AM, Murphy B, Chen W, Khoury SJ, Sayegh MH. Class II MHC allopeptide-specific T-cell clones transfer delayed type hypersensitivity responses in vivo. Transplant Proc. 1997 Feb-Mar; 29(1-2):1008-9.
    View in: PubMed
  300. Mark W, Hechenleitner P, Sayegh MH, Hancock WW, Candinas D. Importance of the CD28/B7 costimulatory pathway in the development of chronic ductopenic rejection in a new model of orthotopic rat liver allotransplantation. Transplant Proc. 1997 Feb-Mar; 29(1-2):1029.
    View in: PubMed
  301. Stadlbauer TH, Onodera K, Schaub M, Korom S, Binder J, Sayegh MH, Kupiec-Weglinski JW. Intrathymic immunomodulation of sensitized rat recipients of cardiac allografts: requirements for allorecognition pathways. Transplant Proc. 1997 Feb-Mar; 29(1-2):1016.
    View in: PubMed
  302. Chowdhury NC, Murphy B, Sayegh MH, Hardy MA, Oluwole SF. Induction of transplant tolerance by intrathymic inoculation of synthetic MHC class I allopeptides. Transplant Proc. 1997 Feb-Mar; 29(1-2):1136.
    View in: PubMed
  303. Nadeau K, Azuma H, Chandraker A, Sayegh MH, Tilney NL. Inhibition of CD28-B7 T-cell costimulatory activation pathway affects intragraft cytokine and growth factor expression in chronic renal allograft rejection. Transplant Proc. 1997 Feb-Mar; 29(1-2):1038.
    View in: PubMed
  304. Onodera K, Hancock WW, Graser E, Volk HD, Lehmann M, Chandraker A, Sayegh MH, Kupiec-Weglinski JW. Th2-type cytokines in the "infectious" tolerance pathway. Transplant Proc. 1997 Feb-Mar; 29(1-2):1290-1.
    View in: PubMed
  305. Knoflach A, Chandraker A, Sayegh MH. Chronic rejection from bedside to bench: role of T cells. Ann Transplant. 1997; 2(2):53-60.
    View in: PubMed
  306. Chowdhury NC, Murphy B, Sayegh MH, Jin MX, Roy DK, Hardy MA, Oluwole SF. Acquired systemic tolerance to rat cardiac allografts induced by intrathymic inoculation of synthetic polymorphic MHC class I allopeptides. Transplantation. 1996 Dec 27; 62(12):1878-82.
    View in: PubMed
  307. Akalin E, Chandraker A, Russell ME, Turka LA, Hancock WW, Sayegh MH. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo. Transplantation. 1996 Dec 27; 62(12):1942-5.
    View in: PubMed
  308. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc Natl Acad Sci U S A. 1996 Nov 26; 93(24):13967-72.
    View in: PubMed
  309. Azuma H, Chandraker A, Nadeau K, Hancock WW, Carpenter CB, Tilney NL, Sayegh MH. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A. 1996 Oct 29; 93(22):12439-44.
    View in: PubMed
  310. Khoury SJ, Gallon L, Verburg RR, Chandraker A, Peach R, Linsley PS, Turka LA, Hancock WW, Sayegh MH. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol. 1996 Oct 15; 157(8):3700-5.
    View in: PubMed
  311. Chen W, Murphy B, Waaga AM, Willett TA, Russell ME, Khoury SJ, Sayegh MH. Mechanisms of indirect allorecognition in graft rejection: class II MHC allopeptide-specific T cell clones transfer delayed-type hypersensitivity responses in vivo. Transplantation. 1996 Sep 27; 62(6):705-10.
    View in: PubMed
  312. Onodera K, Lehmann M, Akalin E, Volk HD, Sayegh MH, Kupiec-Weglinski JW. Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients. J Immunol. 1996 Sep 1; 157(5):1944-50.
    View in: PubMed
  313. Rajasinghe HA, Reddy VM, Hancock WW, Sayegh MH, Hanley FL. Key role of the alternate complement pathway in hyperacute rejection of rat hearts transplanted into fetal sheep. Transplantation. 1996 Aug 15; 62(3):407-11.
    View in: PubMed
  314. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. Am J Med. 1996 Jul; 101(1):49-53.
    View in: PubMed
  315. Murphy B, Sayegh MH. Immunomodulatory function of major histocompatibility complex-derived peptides. Curr Opin Nephrol Hypertens. 1996 May; 5(3):262-8.
    View in: PubMed
  316. Murphy B, Auchincloss H, Carpenter CB, Sayegh MH. T cell recognition of xeno-MHC peptides during concordant xenograft rejection. Transplantation. 1996 Apr 27; 61(8):1133-7.
    View in: PubMed
  317. Perico N, Ostermann D, Bontempeill M, Morigi M, Amuchastegui CS, Zoja C, Akalin E, Sayegh MH, Remuzzi G. Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. J Am Soc Nephrol. 1996 Apr; 7(4):594-601.
    View in: PubMed
  318. Binder J, Lehmann M, Graser E, Hancock WW, Watschinger B, Onodera K, Sayegh MH, Volk HD, Kupiec-Weglinski JW. The effects of nondepleting CD4 targeted therapy in presensitized rat recipients of cardiac allografts. Transplantation. 1996 Mar 15; 61(5):804-11.
    View in: PubMed
  319. Judge TA, Tang A, Spain LM, Deans-Gratiot J, Sayegh MH, Turka LA. The in vivo mechanism of action of CTLA4Ig. J Immunol. 1996 Mar 15; 156(6):2294-9.
    View in: PubMed
  320. Sayegh MH, Khoury SJ, Hancock WW, Weiner HL, Carpenter CB. Mechanisms of oral tolerance by MHC peptides. Ann N Y Acad Sci. 1996 Feb 13; 778:338-45.
    View in: PubMed
  321. Russell ME, Hancock WW, Akalin E, Wallace AF, Glysing-Jensen T, Willett TA, Sayegh MH. Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest. 1996 Feb 1; 97(3):833-8.
    View in: PubMed
  322. Sayegh MH, Krensky AM. Novel immunotherapeutic strategies using MHC derived peptides. Kidney Int Suppl. 1996 Jan; 53:S13-20.
    View in: PubMed
  323. Sayegh MH, Carpenter CB. Role of indirect allorecognition in allograft rejection. Int Rev Immunol. 1996; 13(3):221-9.
    View in: PubMed
  324. Watschinger B, Sayegh MH. Endothelin in organ transplantation. Am J Kidney Dis. 1996 Jan; 27(1):151-61.
    View in: PubMed
  325. Hancock WW, Grey ST, Hau L, Akalin E, Orthner C, Sayegh MH, Salem HH. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation. 1995 Dec 27; 60(12):1525-32.
    View in: PubMed
  326. Binder J, Graser E, Hancock WW, Wasowska B, Sayegh MH, Volk HD, Kupiec-Weglinski JW. Downregulation of intragraft IFN-gamma expression correlates with increased IgG1 alloantibody response following intrathymic immunomodulation of sensitized rat recipients. Transplantation. 1995 Dec 27; 60(12):1516-24.
    View in: PubMed
  327. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, Hancock WW. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol. 1995 Nov 15; 155(10):4521-4.
    View in: PubMed
  328. Fajtova VT, Sayegh MH, Hickey N, Aliabadi P, Lazarus JM, LeBoff MS. Intact parathyroid hormone levels in renal insufficiency. Calcif Tissue Int. 1995 Nov; 57(5):329-35.
    View in: PubMed
  329. Sayegh MH, Turka LA. T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol. 1995 Oct; 6(4):1143-50.
    View in: PubMed
  330. Khoury SJ, Gallon L, Chen W, Betres K, Russell ME, Hancock WW, Carpenter CB, Sayegh MH, Weiner HL. Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med. 1995 Aug 1; 182(2):357-66.
    View in: PubMed
  331. Shin YT, Adams DH, Wyner LR, Akalin E, Sayegh MH, Karnovsky MJ. Intrathymic tolerance in the Lewis-to-F344 chronic cardiac allograft rejection model. Transplantation. 1995 Jun 27; 59(12):1647-53.
    View in: PubMed
  332. Shin YT, Adams DH, Wyner LR, Akalin E, Sayegh MH, Karnovsky MJ. Intrathymic injection of donor splenocytes plus systemic antilymphocyte serum or antilymphocyte serum alone prolongs cardiac allograft survival and inhibits graft arteriosclerosis in the Lewis-to-F344 chronic rejection model. Transplant Proc. 1995 Jun; 27(3):2112-4.
    View in: PubMed
  333. Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med. 1995 May 1; 181(5):1869-74.
    View in: PubMed
  334. Watschinger B, Sayegh MH, Hancock WW, Russell ME. Up-regulation of endothelin-1 mRNA and peptide expression in rat cardiac allografts with rejection and arteriosclerosis. Am J Pathol. 1995 May; 146(5):1065-72.
    View in: PubMed
  335. Remuzzi G, Perico N, Carpenter CB, Sayegh MH. The thymic way to transplantation tolerance. J Am Soc Nephrol. 1995 Mar; 5(9):1639-46.
    View in: PubMed
  336. Russell ME, Wallace AF, Hancock WW, Sayegh MH, Adams DH, Sibinga NE, Wyner LR, Karnovsky MJ. Upregulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation model of chronic cardiac rejection. Transplantation. 1995 Feb 27; 59(4):572-8.
    View in: PubMed
  337. Gallon L, Watschinger B, Murphy B, Akalin E, Sayegh MH, Carpenter CB. The indirect pathway of allorecognition. The occurrence of self-restricted T cell recognition of allo-MHC peptides early in acute renal allograft rejection and its inhibition by conventional immunosuppression. Transplantation. 1995 Feb 27; 59(4):612-6.
    View in: PubMed
  338. Binder J, Hancock WW, Watschinger B, Wasowska B, Sayegh MH, Kupiec-Weglinski JW. The alloantibody network following intrathymic immunomodulation of sensitized rat recipients of cardiac allografts. Transplantation. 1995 Feb 27; 59(4):590-7.
    View in: PubMed
  339. Binder J, Hancock WW, Watschinger B, Wasowska B, Sayegh MH, Kupiec-Weglinski JW. Abrogation of accelerated allograft rejection by intrathymic injection of donor spleen cells is associated with upregulation of donor-reactive IgM, IgG1, and IgG2A, but depression of IgG2B in the circulation and at the graft site. Transplant Proc. 1995 Feb; 27(1):138-41.
    View in: PubMed
  340. Binder J, Hancock WW, Wasowska B, Gallon L, Watschinger B, Sayegh MH, Brock J, Lehmann M, Volk HD, Kupiec-Weglinski JW. Donor-specific transplantation unresponsiveness in sensitized rats following treatment with a nondepleting anti-CD4 MAb is associated with selective intragraft sparing of Th2-like cells. Transplant Proc. 1995 Feb; 27(1):114-6.
    View in: PubMed
  341. Murphy B, Akalin E, Watschinger B, Carpenter CB, Sayegh MH. Inhibition of the alloimmune response with synthetic nonpolymorphic class II MHC peptides. Transplant Proc. 1995 Feb; 27(1):409-10.
    View in: PubMed
  342. Akalin E, Hancock WW, Perico N, Remuzzi G, Imberti O, Carpenter CB, Sayegh MH. Blocking cell microtubule assembly inhibits the alloimmune response in vitro and prolongs renal allograft survival by inhibition of Th1 and sparing of Th2 cell function in vivo. J Am Soc Nephrol. 1995 Jan; 5(7):1418-25.
    View in: PubMed
  343. Brandeis JM, Sayegh MH, Gallon L, Blumberg RS, Carpenter CB. Rat intestinal epithelial cells present major histocompatibility complex allopeptides to primed T cells. Gastroenterology. 1994 Nov; 107(5):1537-42.
    View in: PubMed
  344. Hancock WW, Adams DH, Wyner LR, Sayegh MH, Karnovsky MJ. CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation, and arterial occlusion after endothelial injury. Am J Pathol. 1994 Nov; 145(5):1008-14.
    View in: PubMed
  345. Remuzzi G, Noris M, Benigni A, Imberti O, Sayegh MH, Perico N. Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides. J Exp Med. 1994 Nov 1; 180(5):1967-72.
    View in: PubMed
  346. Sayegh MH, Perico N, Gallon L, Imberti O, Hancock WW, Remuzzi G, Carpenter CB. Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. Transplantation. 1994 Jul 27; 58(2):125-32.
    View in: PubMed
  347. Binder J, Sayegh MH, Watschinger B, Hancock WW, Kupiec-Weglinski JW. Intrathymic injection of donor-specific X-irradiation-sensitive spleen cells abrogates accelerated rejection of cardiac allografts in sensitized rats. Transplantation. 1994 Jul 15; 58(1):80-6.
    View in: PubMed
  348. Hancock WW, Khoury SJ, Carpenter CB, Sayegh MH. Differential effects of oral versus intrathymic administration of polymorphic major histocompatibility complex class II peptides on mononuclear and endothelial cell activation and cytokine expression during a delayed-type hypersensitivity response. Am J Pathol. 1994 Jun; 144(6):1149-58.
    View in: PubMed
  349. Karnovsky MJ, Russell ME, Hancock W, Sayegh MH, Adams DH. Chronic rejection in experimental cardiac transplantation in a rat model. Clin Transplant. 1994 Jun; 8(3 Pt 2):308-12.
    View in: PubMed
  350. Xia W, Sayegh MH, Kirkman RL. Intrathymic injection of allogeneic cells induces indefinite survival of cardiac but not small bowel grafts. Transplant Proc. 1994 Jun; 26(3):1581.
    View in: PubMed
  351. Xia W, Brandeis JM, Sayegh M, Kirkman RL. Mesenteric and intraepithelial lymphocytes are insufficient to cause rejection but able to mediate lethal graft-versus-host disease in small bowel transplants. Transplant Proc. 1994 Jun; 26(3):1508-9.
    View in: PubMed
  352. Sayegh MH, Watschinger B, Carpenter CB. Mechanisms of T cell recognition of alloantigen. The role of peptides. Transplantation. 1994 May 15; 57(9):1295-302.
    View in: PubMed
  353. Frem GJ, Rennke HG, Sayegh MH. Late renal allograft failure secondary to thrombotic microangiopathy-human immunodeficiency virus nephropathy. J Am Soc Nephrol. 1994 Mar; 4(9):1643-8.
    View in: PubMed
  354. Watschinger B, Gallon L, Carpenter CB, Sayegh MH. Mechanisms of allo-recognition. Recognition by in vivo-primed T cells of specific major histocompatibility complex polymorphisms presented as peptides by responder antigen-presenting cells. Transplantation. 1994 Feb 27; 57(4):572-6.
    View in: PubMed
  355. Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 1994; 12:809-37.
    View in: PubMed
  356. Kupiec-Weglinski JW, Wasowska B, Papp I, Schmidbauer G, Sayegh MH, Baldwin WM, Wieder KJ, Hancock WW. CD4 mAb therapy modulates alloantibody production and intracardiac graft deposition in association with selective inhibition of Th1 lymphokines. J Immunol. 1993 Nov 1; 151(9):5053-61.
    View in: PubMed
  357. Adams DH, Russell ME, Hancock WW, Sayegh MH, Wyner LR, Karnovsky MJ. Chronic rejection in experimental cardiac transplantation: studies in the Lewis-F344 model. Immunol Rev. 1993 Aug; 134:5-19.
    View in: PubMed
  358. Khoury SJ, Sayegh MH, Hancock WW, Gallon L, Carpenter CB, Weiner HL. Acquired tolerance to experimental autoimmune encephalomyelitis by intrathymic injection of myelin basic protein or its major encephalitogenic peptide. J Exp Med. 1993 Aug 1; 178(2):559-66.
    View in: PubMed
  359. Sayegh MH, Perico N, Imberti O, Hancock WW, Carpenter CB, Remuzzi G. Thymic recognition of class II major histocompatibility complex allopeptides induces donor-specific unresponsiveness to renal allografts. Transplantation. 1993 Aug; 56(2):461-5.
    View in: PubMed
  360. Hancock WW, Sayegh MH, Kwok CA, Weiner HL, Carpenter CB. Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. Transplantation. 1993 May; 55(5):1112-8.
    View in: PubMed
  361. Sayegh MH, Khoury SJ, Hancock WW, Weiner HL, Carpenter CB. Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat. Transplant Proc. 1993 Feb; 25(1 Pt 1):357-8.
    View in: PubMed
  362. Hancock WW, Sayegh MH, Carpenter CB. In vivo evidence for the Th1/Th2 paradigm: oral alloantigen-induced modulation of accelerated allograft rejection is associated with dense intragraft IL-4. Transplant Proc. 1992 Oct; 24(5):2313-4.
    View in: PubMed
  363. Sayegh MH, Khoury SJ, Hancock WW, Weiner HL, Carpenter CB. Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc Natl Acad Sci U S A. 1992 Aug 15; 89(16):7762-6.
    View in: PubMed
  364. Sablinski T, Sayegh MH, Kut JP, Milford EL, Tilney NL, Kupiec-Weglinski JW. Evidence that therapeutic strategies targeted at CD4+ cells modulate accelerated rejection of cardiac allografts in sensitized rats by different mechanisms. Transplantation. 1992 Aug; 54(2):292-6.
    View in: PubMed
  365. Hancock WW, Sayegh MH, Sablinski T, Kut JP, Kupiec-Weglinski JW, Milford EL. Blocking of mononuclear cell accumulation, cytokine production, and endothelial activation within rat cardiac allografts by CD4 monoclonal antibody therapy. Transplantation. 1992 Jun; 53(6):1276-80.
    View in: PubMed
  366. Hancock WW, Sayegh MH, Zhang ZJ, Kwok CA, Weiner HL, Carpenter CB. Oral immunization with allogeneic splenocytes inhibits development of accelerated but not acute rejection of cardiac grafts: analysis of intragraft effector mechanisms. Transplant Proc. 1992 Feb; 24(1):250-1.
    View in: PubMed
  367. Sablinski T, Sayegh MH, Kut JP, Tilney NL, Milford EL, Kupiec-Weglinski JW. The importance of targeting the CD4+ T cell subset at the time of antigenic challenge for induction of prolonged vascularized allograft survival. Transplantation. 1992 Jan; 53(1):219-21.
    View in: PubMed
  368. Sayegh MH, Zhang ZJ, Hancock WW, Kwok CA, Carpenter CB, Weiner HL. Down-regulation of the immune response to histocompatibility antigens and prevention of sensitization by skin allografts by orally administered alloantigen. Transplantation. 1992 Jan; 53(1):163-6.
    View in: PubMed
  369. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med. 1991 Jun 1; 114(11):954-5.
    View in: PubMed
  370. Cudkowicz ME, Sayegh MH, Rennke HG. Membranous nephropathy in a patient with renal cell carcinoma. Am J Kidney Dis. 1991 Mar; 17(3):349-51.
    View in: PubMed
  371. Sablinski T, Sayegh MH, Kut JP, Hancock WW, Milford EL, Tilney NL, Kupiec-Weglinski JW. Therapeutic strategies targeted at CD4+ cells obviate accelerated rejection of cardiac allografts in sensitized rats. Transplant Proc. 1991 Feb; 23(1 Pt 1):268-9.
    View in: PubMed
  372. Sayegh MH, Sablinski T, Tanaka K, Kut JP, Kwok CA, Tilney NL, Kupiec-Weglinski JW, Milford EL. Effects of BWH-4 anti-CD4 monoclonal antibody on rat vascularized cardiac allografts before and after engraftment. Transplantation. 1991 Feb; 51(2):296-9.
    View in: PubMed
  373. Sablinski T, Sayegh MH, Hancock WW, Kut JP, Kwok CA, Milford EL, Tilney NL, Kupiec-Weglinski JW. Differential role of CD4+ cells in the sensitization and effector phases of accelerated graft rejection. Transplantation. 1991 Jan; 51(1):226-31.
    View in: PubMed
  374. Silverman DH, Sayegh MH, Alvarez CE, Johnson TS, Milford EL, Karnovsky ML. HLA class II-restricted binding of muramyl peptides to B lymphocytes of normal and narcoleptic subjects. Hum Immunol. 1990 Mar; 27(3):145-54.
    View in: PubMed
  375. Sayegh MH, Turka LA, Milford EL, Carpenter CB. Mixed lymphocyte response-generated suppressor cell specificity in humans is major histocompatibility complex-restricted. Hum Immunol. 1989 Dec; 26(4):281-7.
    View in: PubMed
  376. Frankel AH, Sayegh MH, Rothstein DM, Milford EL, Carpenter CB. Requirements for the induction of allospecific CD8+ suppressor T cells in the rat primary mixed lymphocyte response. CD4+, CD45R+ T cells, or supernatant factor. Transplantation. 1989 Oct; 48(4):639-46.
    View in: PubMed
  377. Sayegh MH, Kut JP, Milford EL. Anti-CD4 monoclonal antibody effects cellular hyporesponsiveness and prolongs renal allograft survival in the rat. Hum Immunol. 1989 Oct; 26(2):131-6.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Sayegh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_